Jonathan E. Dowell

7.4k total citations · 1 hit paper
91 papers, 2.5k citations indexed

About

Jonathan E. Dowell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jonathan E. Dowell has authored 91 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Jonathan E. Dowell's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Jonathan E. Dowell is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Jonathan E. Dowell collaborates with scholars based in United States, Canada and Australia. Jonathan E. Dowell's co-authors include David E. Gerber, John D. Minna, Puneeth Iyengar, Hak Choy, Chul Ahn, Zabi Wardak, Robert Timmerman, Peter Kirkpatrick, Randall Hughes and Kenneth D. Westover and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Jonathan E. Dowell

86 papers receiving 2.4k citations

Hit Papers

Consolidative Radiotherapy for Limited Metastatic Non–Sma... 2017 2026 2020 2023 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
    2017 660 citations Puneeth Iyengar, David E. Gerber et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan E. Dowell United States 24 1.4k 1.1k 461 270 266 91 2.5k
Anne M. Traynor United States 32 1.1k 0.8× 1.3k 1.2× 933 2.0× 223 0.8× 293 1.1× 117 2.9k
Ruth Swann United Kingdom 22 1.6k 1.2× 1.1k 1.0× 540 1.2× 237 0.9× 180 0.7× 44 2.7k
Baukelien van Triest Netherlands 25 776 0.6× 1.2k 1.0× 643 1.4× 345 1.3× 202 0.8× 79 2.3k
Bryan J. Schneider United States 26 1.2k 0.9× 1.6k 1.4× 613 1.3× 251 0.9× 334 1.3× 75 2.8k
Pierre-Jean Souquet France 23 2.1k 1.6× 1.5k 1.3× 1.0k 2.2× 191 0.7× 663 2.5× 72 3.2k
Panos Fidias United States 25 1.8k 1.4× 1.7k 1.5× 925 2.0× 210 0.8× 276 1.0× 58 3.0k
Lin Gu United States 27 1.7k 1.3× 1.0k 0.9× 436 0.9× 501 1.9× 268 1.0× 105 2.8k
Tomonori Hirashima Japan 31 1.9k 1.4× 1.7k 1.5× 543 1.2× 246 0.9× 196 0.7× 146 2.7k
Sophie Gourgou France 28 812 0.6× 1.1k 1.0× 358 0.8× 745 2.8× 405 1.5× 123 2.3k
Gavin Wright Australia 27 2.1k 1.5× 1.3k 1.1× 463 1.0× 380 1.4× 434 1.6× 128 3.0k

Countries citing papers authored by Jonathan E. Dowell

Since Specialization
Citations

This map shows the geographic impact of Jonathan E. Dowell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan E. Dowell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan E. Dowell more than expected).

Fields of papers citing papers by Jonathan E. Dowell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan E. Dowell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan E. Dowell. The network helps show where Jonathan E. Dowell may publish in the future.

Co-authorship network of co-authors of Jonathan E. Dowell

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan E. Dowell. A scholar is included among the top collaborators of Jonathan E. Dowell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan E. Dowell. Jonathan E. Dowell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sampath, Sagus, Puneeth Iyengar, Song Zhang, et al.. (2025). Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 87. 103435–103435.
3.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 31(4). 639–648. 1 indexed citations
4.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8597–8597. 1 indexed citations
5.
6.
7.
Zhou, Katherine I., et al.. (2023). P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S337–S338. 1 indexed citations
8.
9.
Dan, Tu, et al.. (2022). Lung Adenocarcinoma Associated With GermlineEGFRR776H Variant: A Case Report and Review of the Literature. JCO Precision Oncology. 6(6). e2100559–e2100559. 6 indexed citations
10.
Dowell, Jonathan E., et al.. (2017). Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. OncoTargets and Therapy. Volume 10. 2057–2066. 15 indexed citations
11.
12.
Tirado, Carlos A, et al.. (2012). The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia. Cancer Genetics. 205(3). 124–127. 3 indexed citations
13.
Keller, Brian C., et al.. (2010). Diffuse Large B-Cell Lymphoma in a Hepatitis C Virus-Infected Patient Presenting With Lactic Acidosis and Hypoglycemia. The American Journal of the Medical Sciences. 339(2). 202–204. 8 indexed citations
14.
Shah, Sachin, et al.. (2010). Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Supportive Care in Cancer. 20(1). 87–93. 10 indexed citations
15.
Dowell, Jonathan E. & John D. Minna. (2008). Small-cell lung cancer: translational research enroute to therapeutic advances.. PubMed. 22(13). 1493, 1495–1493, 1495. 1 indexed citations
16.
Dowell, Jonathan E., et al.. (2006). Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. The American Journal of the Medical Sciences. 331(3). 139–149. 9 indexed citations
17.
Dowell, Jonathan E. & John D. Minna. (2006). EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nature Clinical Practice Oncology. 3(4). 170–171. 15 indexed citations
18.
Dowell, Jonathan E., John D. Minna, & Peter Kirkpatrick. (2005). Erlotinib hydrochloride. Nature Reviews Drug Discovery. 4(5). S14–S15. 24 indexed citations
19.
Dowell, Jonathan E., et al.. (2003). A clinical mass balance study of anidulafungin showing complete fecal elimination. 43. 32. 8 indexed citations
20.
Dowell, Jonathan E., Robert J. Sinard, Denise A. Yardley, et al.. (1999). Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.. PubMed. 9(2 Suppl 1). 97–101. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne M. Traynor Breakdown of academic impact, for papers by Ruth Swann Breakdown of academic impact, for papers by Baukelien van Triest Breakdown of academic impact, for papers by Bryan J. Schneider Breakdown of academic impact, for papers by Pierre-Jean Souquet Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Lin Gu Breakdown of academic impact, for papers by Tomonori Hirashima Breakdown of academic impact, for papers by Sophie Gourgou Breakdown of academic impact, for papers by Gavin Wright
Rankless by CCL
2026